Jump Financial LLC Sells 20,867 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jump Financial LLC reduced its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 59.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,074 shares of the biopharmaceutical company's stock after selling 20,867 shares during the period. Jump Financial LLC's holdings in Catalyst Pharmaceuticals were worth $294,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. abrdn plc purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter worth approximately $10,115,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Catalyst Pharmaceuticals by 131.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company's stock worth $14,570,000 after acquiring an additional 396,506 shares during the period. Vanguard Group Inc. raised its stake in shares of Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock worth $175,957,000 after buying an additional 390,116 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth $6,887,000. Finally, JPMorgan Chase & Co. boosted its holdings in Catalyst Pharmaceuticals by 80.3% during the fourth quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company's stock worth $15,364,000 after buying an additional 327,936 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock traded up $0.65 during mid-day trading on Friday, hitting $24.92. 261,085 shares of the stock traded hands, compared to its average volume of 1,102,137. The company's 50-day simple moving average is $22.76 and its 200-day simple moving average is $22.29. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $26.16. The firm has a market cap of $3.04 billion, a price-to-earnings ratio of 21.08, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares of the company's stock, valued at $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

CPRX has been the subject of several research reports. Bank of America reaffirmed a "buy" rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Stephens restated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Finally, Robert W. Baird upped their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.